Population preference values for treatment outcomes in chronic lymphocytic leukaemia: A cross-sectional utility study

Health and Quality of Life Outcomes

Volumn 8, Issue , 2010, Pages

  Beusterien, Kathleen M ^a   Davies, John ^b   Leach, Michael ^c   Meiklejohn, David ^d   Grinspan, Jessica L ^a   O'Toole, Alison ^e   Bramham Jones, Steve ^e  

^a ICON PLC   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c Leukaemia Research Lab   (United Kingdom)

^d NHS TAYSIDE   (United Kingdom)

^e Napp Pharmaceuticals Limited   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; CHLORAMBUCIL; ANTINEOPLASTIC AGENT;

APPETITE; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; DAILY LIFE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; FATIGUE; FEMALE; HEALTH STATUS; HUMAN; MALE; NAUSEA; NAUSEA AND VOMITING; NIGHT SWEAT; PNEUMONIA; SYMPTOM; TOXICITY; TREATMENT OUTCOME; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; ADOLESCENT; ADULT; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; INTERVIEW; QUALITY OF LIFE; SICKNESS IMPACT PROFILE; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CROSS-SECTIONAL STUDIES; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; INTERVIEWS AS TOPIC; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; QUALITY OF LIFE; SICKNESS IMPACT PROFILE; TREATMENT OUTCOME;

EID: 77952255189     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-8-50     Document Type: Article

References (37)

1. Elphee EE. Caring for patients with chronic lymphocytic leukaemia. Clinical Journal of Oncology Nursing 2008, 12:417-423. 10.1188/08.CJON.417-423, 18515240.
2. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 2007, 12:20-37. 10.1634/theoncologist.12-1-20, 17227898.
3. Shanafelt TD, Bowen D, Venkat C, Slager SL, Zent CS, Kay NE, Reinalda M, Sloan JA, Call TG. Quality of life in chronic lymphocytic leukaemia: An international survey of 1482 patients. British Journal of Haematology 2007, 139:255-264. 10.1111/j.1365-2141.2007.06791.x, 17897301.
4. National Institute for Health and Clinical Excellence (NICE) Guide to the Methods of Technology Appraisal 2008, London: NICE, accessed 11-20-2009, National Institute for Health and Clinical Excellence (NICE)., http://www.nice.org.uk/media/4A6/59/UtilitiesBriefingPaper010607KT.pdf
5. Scottish Medicines Consortium Guidance to Manufacturers for Completion of New Product Assessment Form (NPAF) (Revised June 2007) accessed 11/20/09., http://www.scottishmedicines.org.uk/smc/22.html
6. Scott WG, Scott HM. Economic evaluation of third-line treatment with alemtuzumab for chronic lymphocytic leukaemia. Clin Drug Investig 2007, 27(11):755-64. 10.2165/00044011-200727110-00002, 17914894.
7. Reed SD, Anstrom KJ, Li Y, Schulman KA. Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. Pharmacoeconomics 2008, 26(5):435-46. 10.2165/00019053-200826050-00007, 18429659.
8. Breitscheidel L. Cost utility of allogeneic stem cell transplantation with matched unrelated donor versus treatment with imatinib for adult patients with newly diagnosed chronic myeloid leukaemia. J Med Econ 2008, 11(4):571-84.
9. Levy V, Porcher R, Delabarre F, Leporrier M, Cazin B, Chevret S. Evaluating treatment strategies in chronic lymphocytic leukaemia: Use of quality-adjusted survival analysis. Journal of Clinical Epidemiology 2001, 54:747-754. 10.1016/S0895-4356(00)00359-0, 11438417.
10. Stephens JM, Gramegna P, Laskin B, Botteman MF, Pashos CL. Chronic lymphocytic leukaemia: Economic burden and quality of life: Literature review. American Journal of Therapeutics 2005, 12:460-466. 10.1097/01.mjt.0000104489.93653.0f, 16148431.
11. Hyde B, Wake B, Bryan S, Barton P, Fry-Smith A, Davenport C, Song F. Fludarabine as second-line therapy for B cell chronic lymphocytic leukaemia: a technology assessment. Health Technology Assessment 2002, 6(2):1-89.
12. Fludarabine Annex Cost-effectiveness. 2001, accessed 08-12-2009, Fludarabine Annex., http://www.nice.org.uk/nicemedia/pdf/fludarabine3.pdf
13. Berterö C, Eriksson BE, Ek AC. A substantive theory of quality of life of adults with chronic leukaemia. International Journal of Nursing Studies 1997, 34:9-16. 10.1016/S0020-7489(96)00025-9, 9055116.
14. Pickard AS, Wilke CT, Lin HW, Lloyd A. Health utilities using the EQ-5D in studies of cancer. Pharmacoeconomics 2007, 25:365-384. 10.2165/00019053-200725050-00002, 17488136.
15. Torrance GW. Measurement of health state utilities for economic appraisal. Journal Health Economics 1986, 5:1-30.
16. Redaelli A, Stephens JM, Laskin BL, Pashos CL, Botteman MF. The burden and outcomes associated with four leukaemias: AML, ALL, CLL and CML. Expert Review of Anticancer Therapy 2003, 3(3):311-329. 10.1586/14737140.3.3.311, 12820775.
17. Kermani IA, Dehdilani M, Dolatkhah R. Chronic lymphocytic leukaemia in the recent 10 years and treatment effects of Fludarabin. Asian Pacific Journal of Cancer Prevention 2007, 8:367-371.
18. Holzner B, Kemmler G, Kopp M, Nguyen-Van-Tam D, Sperner-Unterweger B, Greil R. Quality of life of patients with chronic lymphocytic leukaemia: Results of a longitudinal investigation over 1 yr. European Journal of Haematology 2004, 72(6):381-389. 10.1111/j.1600-0609.2004.00233.x, 15128416.
19. Else M, Smith AG, Cocks K, et al. Patients' experience of chronic lymphocytic leukaemia: Baseline health-related quality of life results from the LRF CLL4 trial. British Journal of Haematology 2008, 143(5):690-697. 10.1111/j.1365-2141.2008.07407.x, 19016733.
20. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai RK. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukaemia: Revised guidelines for diagnosis and treatment. Blood 1996, 87:4990-4997.
21. Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. 2006, Cancer Therapy Evaluation Program, Cancer Therapy Evaluation Program.
22. Office of National Statistics Online 2009 Population Estimates for UK, England and Wales, Scotland and Northern Ireland. accessed 03-15-09, Office of National Statistics Online 2009., http://www.statistics.gov.uk/statbase/Product.asp?vlnk=15106
23. Uyl-De Groot CA, Löwenberg B, Vellenga E, Suciu S, Willemze R, Rutten FFH. Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukaemia. Br J Haematology 1998, 100:629-636.
24. Lloyd A, Nafees B, Narewska J, Dewilde S, Watkins J. Health state utilities for metastatic breast cancer. Br J Cancer 2006, 95:683-690. 10.1038/sj.bjc.6603326, 2360509, 16967055.
25. Beusterien KM, Szabo SM, Kotapati S, Mukherjee J, Hoos A, Hersey P, Middleton MR, Levy AR. Societal preference values for advanced melanoma health states in the United Kingdom and Australia. Br J Cancer 2009, 101(3):387-9. Epub 2009 Jul 14, 10.1038/sj.bjc.6605187, 19603025.
26. Szabo SM, Levy AR, Davis C, Holyoake TL, Cortes J. A Multinational Study of Health State Preference Values Associated with Chronic Myelogenous Leukaemia. Value Health 2009, 13:103-111.
27. Bennett K, Torrance G. Measuring health state preferences and utilities: Rating scale, time trade-off and standard gamble techniques. Quality of Life and Pharmacoeconomics in Clinical Trials 1996, Philadelphia: Lippincott-Raven, Spilker B, 2.
28. Dolan P. Modeling valuations for EuroQol health states. Medical Care 1997, 35:1095-1108. 10.1097/00005650-199711000-00002, 9366889.
29. Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Medical Care 2005, 43:736-749. 10.1097/01.mlr.0000172050.67085.4f, 15970790.
30. Tsuchiya A, Ikeda S, Ikegami N, Nishimura S, Sakai I, Fukuda T, Hamashima C, Hisashige A, Tamura M. Estimating an EQ-5D population value set: The case of Japan. Health Economics 2002, 11:341-353. 10.1002/hec.673, 12007165.
31. Levy AR, Krowdley K, Iloeje UH, Tafesse E, Mukherjee J, Gish R, Bzowej N, Briggs AH. The impact of chronic hepatitis B disease progression on quality of life: A multinational study of health state preferences from infected and uninfected persons. Value in Health 2008, 11:527-538. 10.1111/j.1524-4733.2007.00297.x, 18179664.
32. Dale W, Basu A, Elstein A, Meltzer D. Predicting Utility Ratings for Joint Health States from Single Health States in Prostate Cancer: Empirical Testing of 3 Alternative Theories. Med Dec Making 2008, 28:102-112.
33. Fu AX, Kattan MW. Utilities should not be multiplied: evidence from the preference-based scores in the United States. Med Care 2008, 46:984-990. 10.1097/MLR.0b013e3181791a9c, 18725854.
34. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Annals of Medicine 2001, 33:337-343. 10.3109/07853890109002087, 11491192.
35. Kilbridge KL, Cole BF, Kirkwood JM, Haluska FG, Atkins MA, Ruckdeschel JC, Sock DE, Nease RF, Weeks JC. Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data. J Clin Oncol 2002, 20:1311-1318. 10.1200/JCO.20.5.1311, 11870174.
36. Crott R. Cost effectiveness and cost utility of adjuvant interferon alpha in cutaneous melanoma: a review. Pharmacoeconomics 2004, 22:569-580. 10.2165/00019053-200422090-00002, 15209526.
37. Dixon S, Walters SJ, Turner L, Hancock BW. Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: results from randomised trial. Br J Cancer 2006, 94:492-498. 10.1038/sj.bjc.6602973, 2361187, 16449995.